Jonathan E. Rosenberg, MD

Articles

Dr. Rosenberg on the KEYNOTE-045 Trial in Advanced Urothelial Cancer

May 27th 2020

Jonathan E. Rosenberg, MD, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

Dr. Rosenberg on Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

April 1st 2020

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.

Dr. Rosenberg Discusses Challenges in Metastatic Urothelial Carcinoma

November 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses challenges in the treatment of patients with metastatic urothelial carcinoma.

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

October 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

Dr. Rosenberg Discusses Enfortumab Vedotin in Urothelial Carcinoma

June 28th 2018

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma previously treated with an immune checkpoint inhibitor.

Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

September 6th 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer

August 3rd 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with non-metastatic muscle invasive bladder cancer.

Dr. Rosenberg on Frontline Immunotherapy Potential in Bladder Cancer

January 27th 2017

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer

November 30th 2016

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer

July 13th 2016

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses ongoing research of and next steps with atezolizumab (Tecentriq) for the treatment of patients with metastatic urothelial carcinoma.

x